A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Running, not enrolling · Phase 3

Conditions studied: Plaque Psoriasis

In brief

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.

Key facts

Study ID
NCT06550076
Run by
Takeda
People needed
2099
Starts
2024-09-04
Expected to finish
2029-08-05
Last updated by the study team
2026-06-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.